Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. - Wikidata - wikimedia - TriplyDB

Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.

Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.

http://www.wikidata.org/entity/Q34613920

about

Chemokines and Chemokine Receptors in the Development of Lupus Nephritis The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients Cellular targeting in autoimmunity New antibody approaches to lymphoma therapy Current and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling Rationale for B cell targeting in SLE Data quality challenges in systemic lupus erythematosus trials: how can this be optimized?Current and novel therapeutics in the treatment of systemic lupus erythematosus Mechanisms of B cell autoimmunity in SLE.Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients.Novel synthesizing method of pH-dependent doxorubicin-loaded anti-CD22-labelled drug delivery nanosystem Metabolic regulation of organelle homeostasis in lupus T cells Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2 Expression of CXCL12 receptors in B cells from Mexican Mestizos patients with systemic Lupus erythematosus.A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.B-cell-targeted therapies in systemic lupus erythematosus Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies.Treatment of systemic lupus erythematosus: new advances in targeted therapy.Belimumab for the management of systemic lupus erythematosus.CD22 and autoimmune disease.B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune disease.Epratuzumab for systemic lupus erythematosus.Aberrant B-lymphocyte responses in lupus: inherent or induced and potential therapeutic targets.B lymphocytes: development, tolerance, and their role in autoimmunity-focus on systemic lupus erythematosus.Emerging cell and cytokine targets in rheumatoid arthritis.New treatments for inflammatory rheumatic disease.Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE.Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up.IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society. December 5-9, 2010, San Diego, CA USA.CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation.[Recombinant proteins or monoclonal antibodies: comparative properties and interest in systemic lupus erythematosus].Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies.Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study.Epratuzumab modulates B-cell signaling without affecting B-cell numbers or B-cell functions in a mouse model with humanized CD22.

P2860

Q26741199-AEE0C78D-FC04-46C7-ACBB-1B2C9B3A70F3 Q26774993-DCD8190D-F7B2-4B0B-86F2-A13538DAE5A6 Q26824580-ED7A05C4-BA2F-4DD5-A04A-BC3710AE55B9 Q27022373-4DF5740D-E3C9-4E3E-8CBA-0B238191D934 Q27025692-0E498DF7-5DEB-4911-B5A9-48938086CF39 Q28660706-A1385675-9928-45D2-B0CD-D6EC7D95AC05 Q33691812-221C5597-F6EA-4FF5-9497-9F7108106BA8 Q33829700-783500ED-32C3-4B59-9D22-0290B112BB73 Q34267149-69BF2BDB-2C02-4CFC-B264-5C682C9F898C Q34648851-2ECDA847-B4D6-46D3-8D7E-2C65BFFD38DE Q35840704-56D9C1CB-C862-4520-A556-7468F5A94BC9 Q35857405-780DCF3A-CF3A-430D-8603-AA3F32385616 Q36052352-C4BBBAAE-19B2-4E49-8415-06ED942798FF Q36177195-A755590B-6634-4C65-BDF1-DF6CD9B986FF Q36430066-B6E2E977-49D2-445F-B1E7-597AE0FAC962 Q36608536-C2F67A01-2BAC-4D0B-9FE8-971FE716992D Q37308467-F1238BE2-7C75-46E7-84A3-E30BBE36CAD7 Q37729368-CCD6CF00-2DCE-439C-9AA8-73DD674B7CE3 Q37963474-36C09236-CC00-484F-9F0B-6BD396D15162 Q37974990-C200E215-EC43-4704-B47E-846A50D988A1 Q38014539-669559A1-3DBE-4060-B10A-E8064E4641CA Q38053491-3074A6D8-789D-4891-8423-BB4E2C1777D0 Q38086135-69E42F1C-351D-4269-A3C9-83048FB7BC3B Q38091729-902F0DE0-68FF-4A6A-847B-005939926315 Q38095865-68F04648-1263-462E-A336-4B7E947605E8 Q38108851-E36F7009-D770-4B13-9802-039F0CC93334 Q38159695-7574B34F-E015-4CC5-AAC9-0BA9EA4F543A Q38161794-2601FDCB-980C-4155-8B94-D8D5D9E7910A Q38266252-11F0F5B2-5516-4C8B-8125-151BE3FCBA59 Q38598881-984C0006-40BD-4F0D-AE45-A058C2875891 Q38701163-EB930A7E-A4B1-4D6C-9F62-50D154A4C51A Q38931196-80D302F2-CC45-4D01-9805-F239B9114871 Q38979169-10288F5A-6229-40FF-86DB-14ABB68F3BA3 Q42694406-90C374B5-D5ED-4804-B684-7D4824B2EA88 Q42732010-41968E6E-7DE4-4E69-85B2-B21E61F66B97 Q44173489-BF708A20-FAF7-47DA-8A82-889E3B903304 Q45027602-02686725-3A46-43EA-8619-834B0304C0F3 Q49540233-CB97602B-107D-4844-8D1A-288C173822D1 Q50708173-40F278A5-102A-4400-AFE3-E7E6F06592EB Q51676434-10B7CC5D-1B35-45EF-83E4-2DE943862966

P2860

Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.

http://www.wikidata.org/entity/Q34613920

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Epratuzumab targeting of CD22 ...... systemic lupus erythematosus.

@ast

Epratuzumab targeting of CD22 ...... systemic lupus erythematosus.

@en

Epratuzumab targeting of CD22 ...... systemic lupus erythematosus.

@nl

type

label

Epratuzumab targeting of CD22 ...... systemic lupus erythematosus.

@ast

Epratuzumab targeting of CD22 ...... systemic lupus erythematosus.

@en

Epratuzumab targeting of CD22 ...... systemic lupus erythematosus.

@nl

prefLabel

Epratuzumab targeting of CD22 ...... systemic lupus erythematosus.

@ast

Epratuzumab targeting of CD22 ...... systemic lupus erythematosus.

@en

Epratuzumab targeting of CD22 ...... systemic lupus erythematosus.

@nl

P1433

Q34613920-F1928CA1-FF41-41BF-8555-4532C0378E34

P1476

Q34613920-7E7C83BC-7594-4366-B938-618777C58942

P2093

Q34613920-00C70B36-C8F3-4A28-ADF3-BC7DDBE88EFB

Q34613920-04B2BE71-6289-4A9B-8B42-30DCE9BCBD65

Q34613920-0A1CD787-8317-4C85-9F47-58530B035D50

Q34613920-2C2ED13F-6CC4-4CF8-82F1-C0E236D50358

Q34613920-4C399E65-360F-4899-B985-4657DE477D83

Q34613920-56467C7C-0377-4732-AC0A-C31A2781A42E

Q34613920-A5D0C9A0-8E66-4F85-886F-5D7298A67C37

Q34613920-C2581D83-17D4-46C8-9FE2-45027D6D2385

Q34613920-FDDF60E8-48CE-4C6F-AD4D-89644DE64113

P2860

Q34613920-0743EDB5-EF60-4353-A53D-4922A7497B6A

Q34613920-0E33327E-C6DF-41B2-B947-2B62040CAC4D

Q34613920-0F01F710-FB8D-4DF1-A752-BF5DD5F4711B

Q34613920-223CD222-1DF5-4701-A3C9-61D5D90164D7

Q34613920-2AAEC02A-400F-44CC-8801-1F5039CE057B

Q34613920-4013554E-E557-4449-9C0F-B0A4893582A5

Q34613920-50261001-3A23-4B56-8922-7266F789F604

Q34613920-53629E9F-89ED-4FE2-9B80-E39860375C09

Q34613920-5452B3E8-D428-4FF9-AC71-891FB7B045EA

Q34613920-7E48C36D-8158-4327-A813-98422C991F18

P2888

Q34613920-CDA807DE-C3FE-46EC-AC79-E3EF2B611E87

P304

Q34613920-F8D03274-A74B-42D9-989F-C0A1B43024DA

P31

Q34613920-D3458E8D-39CC-464A-BA0D-9E43D491BCF0

P356

Q34613920-E54C538C-79DB-4C63-B004-815CA1A4334F

P433

Q34613920-2CFA881C-5BBB-4DBF-A0BF-2A48C897172F

P478

Q34613920-FC1C86E8-0E8B-42D1-AE8B-688C27756093

P50

Q34613920-863B79B4-B859-4BD4-9EE5-991157E48DDE

P577

Q34613920-6AC717B8-6A78-4A78-85C3-47A63BE77312

P5875

Q34613920-C1ADB19A-3F58-497A-A3ED-A7438121A325

P6179

Q34613920-9F6D57F6-3A51-4B11-814D-7F4159B79698

P698

Q34613920-92810333-6998-49F6-AAAD-245466E080A9

P932

Q34613920-60E085F7-B81D-4856-989A-6DE5748CF663

P356

P1433

Arthritis Research and Therapy

P1476

Epratuzumab targeting of CD22 ...... n systemic lupus erythematosus

@en

P2093

Arne Hansen

http://www.w3.org/2001/XMLSchema#string

Arwed Hostmann

http://www.w3.org/2001/XMLSchema#string

Capucine Daridon

http://www.w3.org/2001/XMLSchema#string

Daniela Blassfeld

http://www.w3.org/2001/XMLSchema#string

Daniela Frölich

http://www.w3.org/2001/XMLSchema#string

David M Goldenberg

http://www.w3.org/2001/XMLSchema#string

Henrik E Mei

http://www.w3.org/2001/XMLSchema#string

Karin Reiter

http://www.w3.org/2001/XMLSchema#string

Thomas Dörner

http://www.w3.org/2001/XMLSchema#string

P2860

A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1)

CD22: an inhibitory enigma

A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen

A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP

The 1982 revised criteria for the classification of systemic lupus erythematosus

Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus

Control of alpha4beta7 integrin expression and CD4 T cell homing by the beta1 integrin subunit.

The beta 7 integrins in mucosal homing and retention.

L-selectin in health and disease.

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

P2888

P304

R204

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/AR3179

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Claudia Giesecke

P577

2010-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47678031

http://www.w3.org/2001/XMLSchema#string

P6179

1025194873

http://www.w3.org/2001/XMLSchema#string

P698

21050432

http://www.w3.org/2001/XMLSchema#string

P932

3046510

http://www.w3.org/2001/XMLSchema#string